Baseline characteristics

Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma · Source last updated 2026-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      223

   2. group Id

      BG001

      value

      222

   3. group Id

      BG002

      value

      445

   units

   Participants

groups

1. description

   Patients receive oral lenalidomide once daily on days 1-21, oral aspirin (or other deep vein thrombosis prophylaxis at the discretion of the principal investigator) once daily on days 1-28, and standard-dose oral dexamethasone once daily on days 1-4, 9-12, and 17-20. Patients with minimal response or no response after 4 cycles of treatment could register for Step 2 treatment with thalidomide and high-dose dexamethasone. Thalidomide was given orally once daily on days 1-28, and dexamethasone once daily on days 1-4, 9-12, and 17-20 for 4 cycles. As the expansion phase was a substudy terminated early with only 7 patients enrolled, the clinical results presented are mainly for the first phase only. Toxicity data are available for both the first phase and the expansion phase.

   id

   BG000

   title

   Arm I (Lenalidomide, Dexamethasone)

2. description

   Patients receive oral lenalidomide and acetylsalicylic acid as in arm I and low-dose oral dexamethasone once daily on days 1, 8, 15, and 22. Patients with minimal response or no response after 4 cycles of treatment could register for Step 2 treatment with thalidomide and low-dose dexamethasone. Thalidomide was given orally once daily on days 1-28, and dexamethasone once daily on days 1, 8, 15, and 22 for 4 cycles. As the expansion phase was a substudy terminated early with only 7 patients enrolled, the clinical results presented are mainly for the first phase only. Toxicity data are available for both the first phase and the expansion phase.

   id

   BG001

   title

   Arm II (Lenalidomide, Low-dose Dexamethasone)

3. description

   Total of all reporting groups

   id

   BG002

   title

   Total

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            36

            upper Limit

            87

            value

            66

         2. group Id

            BG001

            lower Limit

            35

            upper Limit

            85

            value

            65

         3. group Id

            BG002

            lower Limit

            35

            upper Limit

            87

            value

            65

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            91

         2. group Id

            BG001

            value

            101

         3. group Id

            BG002

            value

            192

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            132

         2. group Id

            BG001

            value

            121

         3. group Id

            BG002

            value

            253

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice